ReviewClinical and experimental immunology2018
Therapeutic potential of phages in autoimmune liver diseases.
Review in Clinical and experimental immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Difficult to treat and refractory autoimmune hepatitis: Recent advances in pharmacological management.World journal of hepatology · 2025Review
- Immune Response of an OralViruses · 2022Article
- Lytic Bacteriophage PZL-Ah152 as Biocontrol Measures Against LethalFrontiers in microbiology · 2022Article
- Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Application of Phagotherapy in the Treatment of Burn Patients (Review).Sovremennye tekhnologii v meditsine · 2021Review
- Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic.Journal of clinical medicine · 2020Review
- Phage Therapy of Pneumonia Is Not Associated with an Overstimulation of the Inflammatory Response Compared to Antibiotic Treatment in Mice.Antimicrobial agents and chemotherapy · 2019Article
- Phage Therapy: What Have We Learned?Viruses · 2018Review
- Perspectives of Phage-Eukaryotic Cell Interactions to Control Epstein-Barr Virus Infections.Frontiers in microbiology · 2018Article
- Phage Therapy: Beyond Antibacterial Action.Frontiers in medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune liver disease (ALD) poses a difficult medical challenge, as there is a significant number of patients in whom current therapy offers questionable or no benefit, yet its side effects may be serious, including the development of malignancy. Bacterial viruses (phages) have been recognized increasingly as immunomodulators contributing to immune homeostasis and curbing inflammation. Accumulating data suggest that phages may be useful in immunotherapy of ALD. Phages have been shown to down-regulate the expression and/or production and activity of factors associated with hepatic injury [reactive oxygen species, Toll-like receptor (TLR)-4 activation, nuclear factor kappa B (NF-κB) activation, proinflammatory and procoagulant activities of platelets] and up-regulate the expression and/or production of factors demonstrated as playing a protective role [interleukin (IL)-10, IL-1 receptor antagonist].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.